Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
1 raison identifiée
Auteur de référence en rhumatologie
50 articles scientifiques publiés — un praticien à la pointe de la recherche
✨ Génération du profil synthétique IA en cours…
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Nurse education in practice · 2021
Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
Abstract Purpose: To assess whether MUC1 peptide vaccine produces an immune response and prevents subsequent colon adenoma formation. Patients and Methods: Multicenter, double-blind, placebo-controlled randomized trial in individuals age 40 to 70 with diagnosis of an advanced adenoma ≤1 year from randomization. Vaccine was administered at 0, 2, and 10 weeks with a booster injection at week 53. Adenoma recurrence was assessed ≥1 year from randomization. The primary endpoint was vaccine immunogenicity at 12 weeks defined by anti-MUC1 ratio ≥2.0. Results: Fifty-three participants received the MUC1 vaccine and 50 placebo. Thirteen of 52 (25%) MUC1 vaccine recipients had a ≥2-fold increase in MUC1 IgG (range, 2.9–17.3) at week 12 versus 0/50 placebo recipients (one-sided Fisher exact P < 0.0001). Of 13 responders at week 12, 11 (84.6%) responded to a booster injection at week 52 with a ≥2-fold increase in MUC1 IgG measured at week 55. Recurrent adenoma was observed in 31 of 47 (66.0%) in the placebo group versus 27 of 48 (56.3%) in the MUC1 group [adjusted relative risk (aRR), 0.83; 95% confidence interval (CI), 0.60–1.14; P = 0.25]. Adenoma recurrence occurred in 3/11 (27.3%) immune responders at week 12 and week 55 (aRR, 0.41; 95% CI, 0.15–1.11; P = 0.08 compared with placebo). There was no difference in serious adverse events. Conclusions: An immune response was observed only in vaccine recipients. Adenoma recurrence was not different than placebo, but a 38% absolute reduction in adenoma recurrence compared with placebo was observed in participants who had an immune response at week 12 and with the booster injection.
Cells · 2021
At the early stages of life development, alveoli are colonized by embryonic macrophages, which become resident alveolar macrophages (ResAM) and self-sustain by local division. Genetic and epigenetic signatures and, to some extent, the functions of ResAM are dictated by the lung microenvironment, which uses cytokines, ligand-receptor interactions, and stroma cells to orchestrate lung homeostasis. In resting conditions, the lung microenvironment induces in ResAM a tolerogenic programming that prevents unnecessary and potentially harmful inflammation responses to the foreign bodies, which continuously challenge the airways. Throughout life, any episode of acute inflammation, pneumonia being likely the most frequent cause, depletes the pool of ResAM, leaving space for the recruitment of inflammatory monocytes that locally develop in monocyte-derived alveolar macrophages (InfAM). During lung infection, the local microenvironment induces a temporary inflammatory signature to the recruited InfAM to handle the tissue injury and eliminate the pathogens. After a few days, the recruited InfAM, which locally self-sustain and develop as new ResAM, gain profibrotic functions required for tissue healing. After the complete resolution of the infectious episode, the functional programming of both embryonic and monocyte-derived ResAM remains altered for months and possibly for the entire life. Adult lungs thus contain a wide diversity of ResAM since every infection brings new waves of InfAM which fill the room left open by the inflammatory process. The memory of these innate cells called trained immunity constitutes an immunologic scar left by inflammation, notably pneumonia. This memory of ResAM has advantages and drawbacks. In some cases, lung-trained immunity offers better defense capacities against autoimmune disorders and the long-term risk of infection. At the opposite, it can perpetuate a harmful process and lead to a pathological state, as is the case among critically ill patients who have immune paralysis and are highly susceptible to hospital-acquired pneumonia and acute respiratory distress syndrome. The progress in understanding the kinetics of response of alveolar macrophages (AM) to lung inflammation is paving the way to new treatments of pneumonia and lung inflammatory process.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
JACC. Basic to translational science · 2026 · Journal Article
Chenouard A, Petrier M, Bridonneau C, André E, et al.
Naunyn-Schmiedeberg's archives of pharmacology · 2026 · Journal Article
El-Sehrawy AAMA, Saleh RO, Alzahrani AA, Asiri M, et al.
Case reports in infectious diseases · 2025 · Case Reports
G G, J LH, G MB, E B
The Journal of infectious diseases · 2025 · Journal Article
Jacqueline C, Minetti C, Monzon Fernandez S, Silveira L, et al.
European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2025 · Journal Article
Mukartihal R, Jain K, J H, Kollur R, et al.
BMC veterinary research · 2025 · Journal Article
A S, S AP, J M, P C, et al.
Seminars in arthritis and rheumatism · 2025 · Journal Article
J B, J S, M D
Journal of neural engineering · 2025 · Journal Article
Konrad P, Gelman KR, Lawrence J, Bhatia S, et al.
Work (Reading, Mass.) · 2025 · Journal Article
Fabienne G, Nadège DA, Cecilia C, Alain G, et al.
Rheumatology (Oxford, England) · 2025 · Journal Article
Saxena P, J S, Rana V, Ravi AK, et al.
QJM : monthly journal of the Association of Physicians · 2025 · Journal Article
J S, Sivasami K, Anilkumar AVS, Goel N, et al.
Cureus · 2025 · Journal Article
J N, Gunabooshanam B, Balasubramanian S
Microbial genomics · 2024 · Journal Article
Jacqueline C, Román Soto S, Herrera-Leon S
Nature immunology · 2024 · Published Erratum
Broquet A, Gourain V, Goronflot T, Le Mabecque V, et al.
The Knee · 2024 · Journal Article
J JL, Parasuraman G, Amirtham SM, Francis DV, et al.
Nature immunology · 2024 · Journal Article
Broquet A, Gourain V, Goronflot T, Le Mabecque V, et al.
Cureus · 2024 · Journal Article
Jacqueline D, Lince K, DeMario VK, Zarutskie A, et al.
Anaesthesia and intensive care · 2023 · Journal Article
Azer M, Chandrasekar N, Jacqueline J, Lai V, et al.
Community dentistry and oral epidemiology · 2023 · Journal Article
Homa F, Jacqueline R, Christophe B
Nature communications · 2023 · Journal Article
Char R, Liu Z, Jacqueline C, Davieau M, et al.
Frontiers in microbiology · 2023 · Journal Article
Jacqueline C, Gavilán AM, López-Perea N, Penedos AR, et al.
Nature communications · 2023 · Journal Article
Olawoye IB, Oluniyi PE, Oguzie JU, Uwanibe JN, et al.
Microbiology spectrum · 2022 · Journal Article
Jacqueline C, Del Valle Arrojo M, Bellver Moreira P, Rodríguez Feijóo MA, et al.
American journal of respiratory and critical care medicine · 2022 · Journal Article
Chaumette T, Cinotti R, Mollé A, Solomon P, et al.
Journal of environmental management · 2022 · Journal Article
Serre-Fredj L, Chasselin L, Jolly O, Jacqueline F, et al.
Marine pollution bulletin · 2021 · Journal Article
Serre-Fredj L, Jacqueline F, Navon M, Izabel G, et al.
Cureus · 2021 · Journal Article
Farr S, Berry JA, Berry DK, Marotta DA, et al.
Antimicrobial agents and chemotherapy · 2021 · Journal Article
Jacqueline C, Caillon J, Meyer O, Dailly E, et al.
Cells · 2021 · Journal Article
Martin FP, Jacqueline C, Poschmann J, Roquilly A
Scientific reports · 2021 · Journal Article
Mouton W, Josse J, Jacqueline C, Abad L, et al.
International journal of molecular sciences · 2021 · Journal Article
Roblin C, Chiumento S, Jacqueline C, Pinloche E, et al.
Nurse education in practice · 2021 · Journal Article
Philippa R, Ann H, Jacqueline M, Nicola A
Cureus · 2021 · Journal Article
Vellingiri K, Ethiraj P, S NJ, Shanthappa AH, et al.
Journal of ethnobiology and ethnomedicine · 2021 · Journal Article
Lucía CA, Jacqueline BR, Alberto BL, David BA, et al.
Cureus · 2020 · Journal Article
Mishra D, Nanda SN, Samant S, Tripathy SK, et al.
Infection and immunity · 2020 · Journal Article
Vourc'h M, David G, Gaborit B, Broquet A, et al.
The Journal of infectious diseases · 2020 · Journal Article
Gaborit BJ, Roquilly A, Louvet C, Sadek A, et al.
Nature immunology · 2020 · Published Erratum
Roquilly A, Jacqueline C, Davieau M, Mollé A, et al.
Scientific reports · 2020 · Journal Article
Jacqueline C, Parvy JP, Rollin ML, Faugère D, et al.
Cureus · 2024 · Journal Article
Kg G, J R
Clinical cancer research : an official journal of the American Association for Cancer Research · 2023 · Randomized Controlled Trial
Schoen RE, Boardman LA, Cruz-Correa M, Bansal A, et al.
The Journal of antimicrobial chemotherapy · 2024 · Journal Article
Jacqueline C, Samper-Cativiela C, Monzon Fernandez S, Ugarte-Ruiz M, et al.
Frontiers in microbiology · 2023 · Journal Article
Mekonnen D, Munshea A, Nibret E, Adnew B, et al.
Health economics review · 2025 · Journal Article
Shobha V, Singhai S, Haridas V, V S, et al.
Hip & pelvis · 2024 · Journal Article
Ansari S, Gupta K, Gupta T, Raja BS, et al.
Rheumatology (Oxford, England) · 2025 · Journal Article
Chandwani A, J S, Dwivedi A, Sivasami K, et al.
Autism research : official journal of the International Society for Autism Research · 2024 · Journal Article
Anderson C, Hochheimer S, Warren Z, Butter E, et al.
Hip & pelvis · 2024 · Journal Article
Ansari S, Gupta K, Gupta T, Raja BS, et al.
Cureus · 2025 · Case Reports
K R, J P, R R, B V MM, et al.
Cureus · 2023 · Journal Article
J S, S L, Nair MV, R KT, et al.
Cureus · 2023 · Case Reports
J SK, Waheed MD, Batool S, Holder SS, et al.
Autism research : official journal of the International Society for Autism Research · 2024 · Journal Article
Anderson C, Hochheimer S, Warren Z, Butter E, et al.
✨ Profil synthétique
IA · 20/05/2026Mme Jacqueline Tanazacq est une rhumatologue qui a publié des travaux sur diverses pathologies, notamment le lupus. Ses publications sur PubMed couvrent des essais cliniques, des aspects génétiques et des revues générales. Elle a également contribué à des revues et méta-analyses dans le domaine de la rhumatologie.
Expertises présumées
Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.